GRAIL Q3 2026 Earnings: Galleri Growth Was Offset by Margin Pressure

GRAIL (NASDAQ: GRAL) reported Q3 2026 total revenue of $37.5 million, up 4% from $36.2 million a year earlier, while diluted net loss per share narrowed to $2.21 from $2.46. Galleri revenue and test volume continued to grow, but net loss widened 16% to $103.6 million as gross profitability weakened and sales and marketing spending increased.

Core Financial Results

Revenue growth was led by Galleri screening revenue, while a sharp decline in development services revenue limited companywide growth. Profitability moved in the opposite direction: GAAP gross loss widened, adjusted gross margin fell 13 percentage points, and the adjusted EBITDA loss increased by 29%.

The results cover the three months ended September 30, 2026. GRAIL released them on November 4, 2026.

Adjusted gross profit excludes amortization of intangible assets and stock-based compensation allocated to cost of revenue. Adjusted EBITDA also excludes several noncash and nonoperating items, so both measures should be considered alongside the GAAP losses.

Business and Segment Performance

Galleri screening revenue increased 14% to $37.3 million, accounting for nearly all quarterly revenue. Test volume rose approximately 24% to more than 56,000, meaning volume expanded faster than Galleri revenue. Management cited market education and promotional pricing initiatives as contributors to commercial momentum.

Development services revenue fell to $266,000 from $3.4 million, a decline of approximately 92%. This reduction explains why total revenue grew only 4% even though Galleri revenue increased at a double-digit rate.

For the nine months ended September 30, 2026, Galleri test volume rose 36% to more than 174,000, while Galleri revenue increased 24% to $119.7 million. These year-to-date figures are separate from the quarterly results.

Volume Growth Outpaced Revenue While Screening Costs Rose

The relationship among test volume, revenue, and direct costs was the quarter’s central operating issue. Galleri volume increased approximately 24%, but Galleri revenue rose 14%, suggesting lower realized revenue per test or a change in pricing and mix. The company specifically identified promotional pricing as one factor supporting commercial traction.

At the same time, cost of screening revenue excluding intangible-asset amortization rose approximately 39% to $22.0 million from $15.9 million. Because screening costs grew faster than screening revenue, adjusted gross margin declined to 42% from 55%.

GAAP gross results also include $33.5 million of quarterly intangible-asset amortization, unchanged from the prior-year period. This expense was the principal reason GRAIL reported a GAAP gross loss despite generating positive adjusted gross profit.

Profitability and Balance Sheet

Sales and marketing expense increased approximately 63% to $41.7 million, consistent with GRAIL’s efforts to expand commercial adoption. General and administrative expense rose approximately 9% to $40.7 million, while research and development expense declined approximately 9% to $44.1 million. Overall costs and operating expenses increased to $182.2 million from $161.5 million, contributing to the wider operating loss.

The improvement in loss per share did not reflect an improvement in absolute earnings. Net loss widened to $103.6 million, but weighted-average diluted shares increased to 46.8 million from 36.1 million. The larger share count caused the per-share loss to narrow even as the total loss increased.

GRAIL ended the quarter with $788.7 million in cash, cash equivalents, and short-term marketable securities, including $29.0 million of cash and $759.7 million of securities. That combined balance was approximately $115.7 million below the $904.4 million held at December 31, 2025. The supplied release did not include a cash flow statement, so this balance-sheet movement should not be treated as a measure of quarterly operating cash flow.

Regulatory and Clinical Progress for Galleri

An FDA advisory committee voted in favor of approving Galleri in September, and GRAIL anticipates an FDA decision by early Q1 2027. However, Galleri had not been cleared or approved by the FDA as of the earnings release, making the agency’s final decision a major upcoming event for potential access and reimbursement.

GRAIL also published results from the NHS-Galleri and PATHFINDER 2 studies, covering approximately 175,000 participants in the UK and North America. The company reported that the studies showed 4 to 6.5 times more cancers detected. In the NHS-Galleri trial, the Galleri arm also recorded a greater than 20% reduction in Stage IV diagnoses for 12 prespecified aggressive cancers and a 25% reduction in cancers diagnosed after emergency presentation compared with the control arm.

Risks Investors Need to Watch

• FDA approval remains pending: The favorable advisory committee vote is an important milestone, but Galleri was not FDA-cleared or approved at quarter-end. The final regulatory outcome could affect access and reimbursement.
• Commercial growth is not yet translating into better margins: Test volume rose faster than revenue, while direct screening costs increased faster than both. Continued promotional pricing could support adoption while pressuring revenue per test and gross margin.
• Losses remain substantial: The net loss widened to $103.6 million and the adjusted EBITDA loss reached $92.6 million, despite higher Galleri revenue.
• Liquidity is declining: Cash and short-term securities decreased by approximately $115.7 million from the end of 2025 through September 2026. Continued operating losses could produce further balance-sheet pressure.
• Non-screening revenue is volatile: Development services revenue fell approximately 92%, limiting total revenue growth and increasing the company’s dependence on Galleri screening revenue.

Summary

GRAIL’s Q3 2026 results showed continued Galleri adoption, with higher test volume and screening revenue, but the growth came alongside weaker unit economics, a lower adjusted gross margin, and wider operating and adjusted EBITDA losses. The next major operating questions are whether GRAIL can convert rising test volume into improved gross profitability and whether the anticipated FDA decision supports broader access and reimbursement for Galleri.